Dr Horwitz on the FDA Approval of Omidubicel in Blood Cancers Requiring Transplant
Mitchell E. Horwitz, MD, discusses the significance of omidubicel as an FDA-approved treatment option to reduce the risk of infection in patients with blood cancers and highlights key findings from the pivotal phase 3 trial.
Dr. Horwitz on the Clinical Benefit of Omidubicel Transplant in Hematologic Malignancies
Mitchell E. Horwitz, MD, discusses the use of omidubicel versus standard myeloablative umbilical cord blood transplant in patients with hematologic malignancies.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512